Gene targeting in the mouse is a powerful tool to study mammalian gene function. The possibility to efficiently introduce somatic mutations in a given gene, at a chosen time and/or in a given cell type will further improve such studies, and will facilitate the generation of animal models for human diseases. To create targeted somatic mutations in the epidermis, we established transgenic mice expressing the bacteriophage P1 Cre recombinase or the tamoxifen-dependent Cre-ERT2 recombinase under the control of the human keratin 14 (K14) promoter. We show that LoxP flanked (floxed) DNA segments were efficiently excised in epidermal keratinocytes of K14-Cre transgenic mice. Furthermore, Tamoxifen administration to adult K14-Cre-ERT2 mice efficiently induced recombination in the basal keratinocytes, whereas no background recombination was detected in the absence of ligand treatment. These two transgenic lines should be very useful to analyse the functional role of a number of genes expressed in keratinocytes.

Keywords:
Somatic mutagenesis, Cre/Lox, Tamoxifen, Keratinocytes, Epidermis, Hair follicle, Mouse
1.
Fuchs E: Of mice and men: Genetic disorders of the cytoskeleton. Mol Biol Cell 1997;8:189–203.
2.
Hardy MH: The secret life of the hair follicle. Trends Genet 1992;8:55–61.
3.
Paus R, Cotsarelis G: The biology of hair follicles. New Eng J Med 1999;341:491–497.
4.
Capecchi MR: The new mouse genetics: Altering the genome by gene targeting. Trends Genet 1989;5:70–76.
5.
Jaenisch R: Transgenic animals. Science 1988;240:1468–1474.
6.
Rajewsky K, Gu H, Kühn R, Betz UAK, Müller W, Roes J, Schwenk F: Conditional gene targeting. J Clin Invest 1996;98:600–603.
7.
Olson EN, Arnold HH, Rigby PWJ, Wold BJ: Know your neighbors: Three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 1996;85:1–4.
8.
Nagy A: Cre recombinase: The universal reagent for genome tailoring. Genesis 2000;26:99–109.
9.
Metzger D, Feil R: Engineering the mouse genome by site-specific recombination. Curr Opin Biotechnol 1999;10:470–476.
10.
Metzger D, Chambon P: Site- and time-specific gene targeting in the mouse. Methods 2001;24:71–80.
11.
Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P: Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 1996;93:10887–10890.
12.
Feil R, Wagner J, Metzger D, Chambon P: Regulation of Cre recombinase activity by mutated oestrogen receptor ligand-binding domains. Biochem Biophys Res Comm 1997;237:752–757.
13.
Brocard J, Warot X, Wendling O, Messaddeq N, Vonesch JL, Chambon P, Metzger D: Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci USA 1997;94:14559–14563.
14.
Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D: Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: Comparison of the recombinase activity of the tamoxifen-inducible Cre-ERT and Cre-ERT2 recombinases. Nucl Acid Res 1999;27:4324–4327.
15.
Imai T, Chambon P, Metzger D: Inducible site-specific somatic mutagenesis in mouse hepatocytes. Genesis 2000;26:147–148.
16.
Imai T, Jiang M, Chambon P, Metzger D: Impaired adipogenesis and lipolysis in the mouse upon Cre-ERT2-mediated selective ablation of RXRα in adipocytes. Proc Natl Acad Sci USA 2001;98:224–228.
17.
Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D, Chambon P: Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature 2000;407:633–636.
18.
Byrne C, Tainsky M, Fuchs E: Programming gene expression in developing epidermis. Development 1994;120:2369–2383.
19.
Vasioukhin V, Degenstein L, Wise B, Fuchs E: The magical touch: Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci USA 1999;96:8551–8556.
20.
Li M, Chiba H, Warot X, Messaddeq N, Gérard C, Chambon P, Metzger D: RXRα ablation in skin keratinocytes results in alopecia and epidermal alterations, Development 2001;128:675–688.
21.
Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E: Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci USA 1989;86:1563–1567.
22.
Wang X, Zinkel S, Polonsky K, Fuchs E: Transgenic studies with a keratin promoter-driven growth hormone transgene: Prospects for gene therapy. Proc Natl Acad Sci USA 1997;94:219–226.
23.
Mascrez B, Mark M, Dierich A, Ghyselinck N B, Kastner P, Chambon P: The RXRα ligand-dependent activation function 2 (AF-2) is important for mouse development. Development 1998;125:4691–4707.
24.
Soriano P: Generalized lacZ expression with the ROSA26 Cre reporter strain. Nature Genet 1999;21:70–71.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.